Cargando…
Only Follow-Up of Memory B Cells Helps Monitor Rituximab Administration to Patients with Neuromyelitis Optica Spectrum Disorders
INTRODUCTION: Neuromyelitis optica spectrum disorders (NMOSD) are identified as a spectrum of inflammatory demyelinating disorders involving the brain, spinal cord and optic nerves. These disorders require early diagnosis and highly active immunosuppressive treatment. Rituximab (RTX) has demonstrate...
Autores principales: | Lebrun, Christine, Cohen, Mikael, Rosenthal-Allieri, Maria Alessandra, Bresch, Saskia, Benzaken, Sylvia, Marignier, Romain, Seitz-Polski, Barbara, Ticchioni, Michel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283795/ https://www.ncbi.nlm.nih.gov/pubmed/29881979 http://dx.doi.org/10.1007/s40120-018-0101-4 |
Ejemplares similares
-
The Balance in T Follicular Helper Cell Subsets Is Altered in Neuromyelitis Optica Spectrum Disorder Patients and Restored by Rituximab
por: Nicolas, Philippe, et al.
Publicado: (2019) -
Pregnancy outcome in patients with neuromyelitis optica spectrum disorder treated with rituximab: A case-series study
por: Seyed Ahadi, Maral, et al.
Publicado: (2021) -
Kappa Free Light Chains, Soluble Interleukin-2 Receptor, and Interleukin-6 Help Explore Patients Presenting With Brain White Matter Hyperintensities
por: Levraut, Michael, et al.
Publicado: (2022) -
Visual Evoked Potentials in Neuromyelitis Optica Spectrum Disorders
por: Hernandez Fustes, Otto Jesus, et al.
Publicado: (2021) -
Antibodies to aquaporin-1 are not present in neuromyelitis optica
por: Schanda, Kathrin, et al.
Publicado: (2015)